本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日分别召开第八届董事会第十四次会议及第八届监事会第九次会议，全票审议 通过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在不影 响募集资金正常使用的情况下，使用最高额度不超过人民币 5,000 万元（包含 本数）的暂时闲置募集资金适时进行现金管理，授权期限自本次董事会审议通 过之日起 12 个月，在上述额度和期限内，资金可循环滚动使用。公司独立董事 对本次事项发表了明确同意的独立意见，保荐机构国金证券股份有限公司出具 了明确同意的核查意见，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意厦门特宝生物工程股份有限公司 首次公开发行股票注册的批复》（证监许可〔2019〕2828 号）核准，并经上海 证券交易所"自律监管决定书〔2020〕21 号"批准，公司首次公开发行人民币 普通股（A 股）4,650 万股，每股发行价格 8.24 元，本次募集资金总额为人民 币 ...

厦门特宝生物工程股份有限公司 独立董事关于第八届董事会第十四次会议相关事项 的独立意见 我们作为厦门特宝生物工程股份有限公司（以下简称"公司"）的独立 董事，根据《上市公司独立董事规则》《上海证券交易所科创板股票上市规 则》《上市公司治理准则》和《公司章程》等有关规定，在认真审阅公司第 八届董事会第十四次会议相关事项后，发表独立意见如下： 一、《关于公司 2023 年半年度募集资金存放与实际使用情况的专项报告 的议案》 公司 2023 年半年度募集资金的存放与使用符合《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》以及公司募集资金管理制度等相关规定，不存在违规使用募集资金的 情形，不存在变相改变募集资金用途和损害股东利益的情形。公司编制的 《2023 年半年度募集资金存放与实际使用情况的专项报告》真实地反映了报 二、《关于使用部分闲置募集资金进行现金管理的议案》 签字： 签字： 姓名：蒋晓蕙 在确保不影响募投项目建设进展和保证资金安全的前提下，公司使用部 分暂时闲置募集资金进行现金 ...

由于募集资金投资项目建设需要一定周期，结合公司募集资金投资项目的推 进计划，公司部分募集资金存在暂时闲置的情形。 国金证券股份有限公司 关于厦门特宝生物工程股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 国金证券股份有限公司（以下简称"保荐机构"）作为厦门特宝生物工程股 份有限公司（以下简称"特宝生物"或"公司"）首次公开发行股票并在科创板 上市的保荐机构，根据《证券发行上市保荐业务管理办法》《科创板上市公司自 律监管指引第 1 号——规范运作》《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》《上海证券交易所科创板股票上市规则（2020 年 12 月修订）》等有关法律法规和规范性文件的要求，对特宝生物拟将部分闲置 募集资金进行现金管理情况进行了审慎核查，并发表核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意厦门特宝生物工程股份有限公司首 次公开发行股票注册的批复》（证监许可〔2019〕2828 号）核准，并经上海证 券交易所"自律监管决定书〔2020〕21 号"批准，公司首次公开发行人民币普 通股（A 股）4,650 万股，每股发行价格 8.24 元 ...

证券代码：688278 证券简称：特宝生物 公告编号：2023-025 厦门特宝生物工程股份有限公司 2023 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）根据中国证券监督 管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》和《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等有关规定，现将公司 2023 年半年度募集资金存放与实际使用情况专项报 告如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账情况 根据中国证券监督管理委员会《关于同意厦门特宝生物工程股份有限公司 首次公开发行股票注册的批复》（证监许可〔2019〕2828 号）核准，并经上海 证券交易所"自律监管决定书〔2020〕21 号"批准，公司向社会首次公开发行 人民币普通股（A 股）4,650 万股，每股发行价为 8.24 元，本次募集资金总额 为人民币 38,316.00 万元，根据有关规定扣除发行 ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 419,307,024.70, representing a year-on-year increase of 21.53%[4] - The net profit attributable to shareholders was RMB 84,173,127.64, reflecting a growth of 46.51% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 102,455,003.37, an increase of 35.62% year-on-year[4] - The basic earnings per share for the period was RMB 0.21, up by 50.00% from the previous year[4] - In Q1 2023, the company reported a net profit of ¥84,173,127.64, an increase of 46.5% compared to ¥57,452,423.77 in Q1 2022[20] - Operating profit for Q1 2023 was ¥118,990,858.09, up 33.5% from ¥89,006,711.83 in the same period last year[20] - Total revenue from sales and services received in Q1 2023 was ¥379,091,244.26, a rise from ¥368,702,244.57 in Q1 2022, reflecting a growth of 2.1%[21] - The company’s total comprehensive income for Q1 2023 was ¥84,173,127.64, an increase of 46.5% from ¥57,452,423.77 in Q1 2022[20] Research and Development - The total R&D investment amounted to RMB 70,109,028.96, which is a significant increase of 71.26% compared to the previous year[4] - The proportion of R&D investment to operating revenue was 16.72%, which increased by 4.85 percentage points year-on-year[5] - The company incurred research and development expenses of ¥37,712,423.75 in Q1 2023, significantly higher than ¥20,347,219.38 in Q1 2022, marking an increase of 85.7%[20] Cash Flow and Assets - The cash flow from operating activities was RMB 21,847,454.23, showing a decrease of 73.66% year-on-year[4] - The company’s cash flow from operating activities in Q1 2023 was ¥21,847,454.23, down 73.7% from ¥82,949,425.82 in Q1 2022[22] - The company's cash and cash equivalents increased to CNY 520,779,757.78 from CNY 301,240,536.26 at the end of 2022, representing a growth of 73%[14] - The company’s cash and cash equivalents at the end of Q1 2023 totaled ¥519,870,257.78, an increase from ¥491,191,572.08 at the end of Q1 2022[23] Assets and Liabilities - The total assets at the end of the reporting period were RMB 1,845,004,186.33, an increase of 4.32% from the end of the previous year[5] - As of March 31, 2023, total current assets were CNY 961,471,381.59, slightly up from CNY 955,610,910.65 at the end of 2022[14] - Non-current assets totaled CNY 883,532,804.74 as of March 31, 2023, compared to CNY 812,948,736.66 at the end of 2022, indicating an increase of 8.7%[15] - The company's total liabilities decreased to CNY 353,230,727.24 from CNY 360,959,315.86 at the end of 2022, a reduction of 2%[16] - The retained earnings increased to CNY 614,970,718.03 from CNY 530,797,590.39, reflecting a growth of 15.8%[17] Shareholder Information - The company reported a total of 5,888 common shareholders at the end of the reporting period[8]

证券代码：688278 证券简称：特宝生物 公告编号：2023-014 厦门特宝生物工程股份有限公司关于 参加 2022 年度生物制品专场集体业绩说明会的公告 投资者可于 4 月 25 日（星期二）16:00 前通过邮件、电话、传真等形式 将需要了解和关注的问题提前提供给公司，公司将在文字互动环节对投资者普遍 关注的问题进行回答。 厦门特宝生物工程股份有限公司（以下简称"公司"）已于 2023 年 3 月 31 日在上海证券交易所披露了公司 2022 年年度报告，为便于广大投资者更全面深 入地了解公司 2022 年度经营成果、财务状况和发展理念，公司参与了由上海证 券交易所主办的 2022 年度生物制品专场集体业绩说明会，此次活动将采用视频 和网络文字互动的方式举行，投资者可登录上海证券交易所上证路演中心 （http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 本次投资者说明会以视频和网络互动形式召开，公司将针对 2022 年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、方式 ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥1.53 billion, representing a 34.86% increase compared to ¥1.13 billion in 2021[17]. - The net profit attributable to shareholders for 2022 was approximately ¥287 million, a 58.40% increase from ¥181 million in 2021[17]. - The net cash flow from operating activities for 2022 was approximately ¥363 million, reflecting a 54.68% increase from ¥234 million in 2021[17]. - The total assets at the end of 2022 were approximately ¥1.77 billion, a 24.18% increase from ¥1.42 billion at the end of 2021[17]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥1.41 billion, a 21.21% increase from ¥1.16 billion at the end of 2021[17]. - The basic earnings per share for 2022 were ¥0.71, a 57.78% increase from ¥0.45 in 2021[18]. - The diluted earnings per share for 2022 were also ¥0.71, reflecting the same percentage increase as basic earnings per share[18]. - The weighted average return on equity (ROE) was 22.41%, up from 16.79% in the previous year, indicating improved profitability[22]. - The company achieved total operating revenue of 1,526,905,123.64 CNY, representing a year-on-year growth of 34.86%[72]. - The net profit attributable to shareholders reached 287,019,900 CNY, with a year-on-year increase of 58.40%[72]. Research and Development - The company has been focusing on the development of long-acting interferon products, which are expected to enhance treatment efficacy and reduce administration frequency[12]. - The company aims to continue its investment in research and development for new products and technologies to maintain competitive advantage in the biotech sector[12]. - Research and development (R&D) expenses accounted for 13.59% of operating revenue, reflecting the company's commitment to innovation[22]. - The company reported a total R&D investment of approximately ¥207.43 million, an increase of 24.12% compared to the previous year[53]. - The company has accumulated 222 patent applications, with 197 patents granted, including 57 new patents obtained during the reporting period[52]. - The company has established a comprehensive R&D building, which will serve as a key driver for high-quality development upon completion[28]. - The company is advancing multiple clinical research projects, including YPEG-G-CSF, which is in the process of applying for domestic drug registration[28]. - The company is focusing on innovative drug development, including projects targeting chronic hepatitis B and cancer treatment[58]. - The company has developed a core technology platform for PEGylation of recombinant proteins, which enhances drug properties and reduces immunogenicity, ensuring sustainable drug innovation and industrialization capabilities[49]. Corporate Governance - The company has received a standard unqualified audit report from Rongcheng Accounting Firm[3]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company does not have any special arrangements for corporate governance[6]. - The governance structure is continuously improved to ensure compliance with relevant laws and regulations, safeguarding shareholder interests[129]. - The company has established a robust investor relations management system to maintain effective communication with investors[130]. - The company has established specialized committees, including audit, nomination, compensation, and strategy committees, to enhance governance[146]. - The company has implemented a differentiated salary structure based on job responsibilities and performance indicators, ensuring competitive compensation aligned with industry standards[153]. Market and Product Development - The company is actively expanding its market presence and exploring potential mergers and acquisitions to enhance growth opportunities[12]. - The company is enhancing its marketing system and academic service capabilities to deepen market potential for core products[31]. - The company is focusing on the research, production, and sales of recombinant proteins and long-acting modified drugs, aiming to be a leader in systemic immune solutions for major diseases like viral hepatitis and malignant tumors[35]. - The company has launched four products: Pegbinterferon, Terlizi, Terlil, and Terlank, with Pegbinterferon being the world's first 40kD pegylated interferon α-2b injection, recognized as a Class 1 new drug in China[35]. - The company is conducting clinical research for the clinical cure of chronic hepatitis B using Peginterferon α-2b injection, with all subjects recruited[104]. - The company is focusing on the development of Y-type polyethylene glycol recombinant human granulocyte colony-stimulating factor (YPEG-GCSF) for chemotherapy-induced neutropenia[104]. Risk Management - The company has detailed potential risks and countermeasures in the report, emphasizing the importance of risk awareness for investors[3]. - The report includes a forward-looking statement risk declaration, indicating that future plans and strategies do not constitute a commitment to investors[5]. - The company faces risks related to technological upgrades and potential patent issues that could impact its core competitiveness[65]. - The company is exposed to risks from changes in tax policies, particularly regarding high-tech enterprise status and VAT exemptions[68]. - The company is at risk of increased bad debts as accounts receivable may rise with expanded sales, depending on customer credit conditions[68]. - The company faces pricing risks due to ongoing healthcare reforms and increased competition in the pharmaceutical market[114]. Social Responsibility and Environmental Impact - The company invested CNY 13.74 million in environmental protection during the reporting period[169]. - The company is actively involved in social responsibility projects aimed at improving the treatment rates for chronic hepatitis B patients, contributing to public health initiatives[167]. - The company emphasizes the integration of ESG principles into its operational decisions, aiming for sustainable development[167]. - The company has established an environmental management system compliant with ISO 14001 standards, which was successfully audited in 2022[180]. - The company has implemented energy management systems to improve energy efficiency and reduce carbon emissions[167]. - The company has supported the "China Chronic Hepatitis B Clinical Cure (Everest) Project" since 2018 to improve the treatment level for hepatitis B patients[189]. Employee Management - The total number of employees in the parent company and major subsidiaries is 1,547, with 1,517 in the parent company and 30 in major subsidiaries[152]. - The employee composition includes 849 sales personnel, 268 R&D staff, and 149 production workers, highlighting a strong emphasis on sales and research capabilities[152]. - The company has a clear cash dividend condition, requiring positive distributable profits and no major investment plans within the next twelve months[156]. - The company has created a talent training system with various programs aimed at enhancing employee skills and organizational alignment[154]. Investor Relations - The company emphasizes the importance of information disclosure, adhering to legal requirements and principles of accuracy and timeliness[199]. - Communication with investors is conducted through various channels, including investor hotlines and performance briefings, to enhance transparency[199]. - The company utilizes new media for investor relations management, including creating annual report interpretation videos and conducting online investor surveys[197]. - The company held four performance briefings during the reporting period to enhance communication with investors[196].